Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    • News in Focus
        • Browse News Releases

        • All News Releases
        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • View All People & Culture

    • Hamburger menu
    • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
    • Create a Free Account
      • ALL CONTACT INFO
      • Contact Us


        11AM ET Sunday – 8PM ET Friday

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Why PRWeb
    • Contact
      • Send a Release
      • Sign up
      • Log in
      • Resources
      • RSS
      • GDPR
      • 2 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Sign up
      • Log in
      • Resources
      • RSS
      • GDPR
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Choose an Affordable Anti-Herpes Product; polyDNA Recommends Gene-Eden-VIR


      News provided by

      PolyDNA

      Dec 30, 2013, 03:00 ET

      Share this article

      Share this article


      Gene-Eden-VIR is the most affordable herpes remedy on the market.
      Gene-Eden-VIR is the most affordable herpes remedy on the market.

      Rochester, NY (PRWEB) December 30, 2013 -- polyDNA recommends Gene-Eden-VIR as the most affordable means of treating a latent herpes infection. As the winter holidays pass, and people break the bank on presents, polyDNA is doing its part to make it easy for individuals to afford a natural remedy against the latent herpes virus.

      'We recommend that individuals make New Year’s resolutions that improve their bank account. Choosing Gene-Eden-VIR, an affordable, clinically proven herpes remedy, is a great way to live up to that sort of resolution.' – Mike Evans, polyDNA

      Post this

      This week, the media, government agencies, not-for-profits, schools, financial institutions and businesses of all kinds are putting up “After Christmas Sales” or are reminding people why their products or services are better than someone else’s. To help customers who suffer from herpes infections, polyDNA compared the cost of Valtrex, Acyclovir (Zovirax), and Gene-Eden-VIR. The first two are FDA approved medications while the third is a natural, antiviral remedy. The first two target the active herpes virus, while the third was designed to target the latent virus.

      “I spent so much money on my kids this Christmas! Somehow, the threat of a herpes outbreak kind of got pushed to the back of my mind. I know for sure I won’t have the money to afford Valtrex over the next few months, and that’s especially true since I lost my insurance too. Things just seem to get harder and harder!” – Tamicka R.

      According to goodrx.com, the cost of a month’s supply of Valtrex (90 pills), one of the most common anti-herpes medications, is $1401.00 for the brand name at the CVS Pharmacy. (1) The cost of the generic brand is only slightly less.

      While Zovirax (Acyclovir) is significantly cheaper, this herpes medication still costs at least $148.41 for oral suspension. (2)

      Gene-Eden-VIR is the only natural antiviral product that was tested according to FDA guidelines for safety and efficacy. A month’s supply of Gene-Eden-VIR is $37.99. That’s $110.42 cheaper than Zovirax, and well over $1,000 cheaper than Valtrex.

      “We recommend that individuals make New Year’s resolutions that improve their bank account. Choosing Gene-Eden-VIR, an affordable, clinically proven herpes remedy, is a great way to live up to that sort of resolution.” – Mike Evans, polyDNA

      In a post marketing clinical study published on August 12, 2013 in the peer reviewed medical journal Pharmacology & Pharmacy in a special edition on Advances in Antiviral Drugs, researchers showed that Gene-Eden-VIR is safe and effective (3). Additionally, up to 70% of those studied reported a decrease in viral symptoms, and users experienced an increase in overall health (3).

      Each ingredient of Gene-Eden-VIR was chosen through a scientific approach. Scientists scanned thousands of scientific and medical papers published in various medical and scientific journals around the world to identify the safest, most effective natural ingredients that target the latent form of herpes. (3)

      To learn more about Gene-Eden-VIR, visit http://www.gene-eden-kill-virus.com. All orders of Gene-Eden-VIR are completely confidential, and no information is shared or sold to any third party. Privacy is assured.

      Reference:

      (1) Goodrx.com - Prices for 90 tablets of Valtrex 1g (brand).
               http://www.goodrx.com/valacyclovir#/?filter-location=&coords=&label=Valtrex&form=tablet&strength=1g&quantity=custom&qty-custom=90

      (2) Goodrx.com - Prices for 200 ml of 200mg/5ml Zovirax oral suspension (brand).
               http://www.goodrx.com/acyclovir#/?filter-location=&coords=&label=Zovirax&form=oral+suspension&strength=200mg&quantity=custom&qty-custom=30

      (3) Gene-Eden-VIR Is Antiviral: Results of a Post Marketing
      Clinical Study. Published on August 12, 2013.
           http://gene-eden-kill-virus.com/PP_Gene-Eden-VIR-is-Antiviral.pdf

      polyDNA is a biotechnology company that develops dietary supplements using the unique scientific method developed by Dr. Hanan Polansky, which is based on Computer Intuition.

      In addition to his unique scientific method, Dr. Polansky published the highly acclaimed scientific discovery, called Microcompetition with Foreign DNA. The discovery explains how foreign DNA fragments, and specifically, DNA of latent viruses, cause most major diseases.

      polyDNA developed Gene-Eden-VIR , an antiviral natural remedy that helps the immune system kill latent viruses.

      Mike Davis, PolyDNA, http://gene-eden-kill-virus.com/, +1 5852509999, [email protected]

      Modal title

      Contact PRWeb

      • 11AM ET Sunday – 8PM ET Friday
      • Contact Us

      About PRWeb

      • About PRWeb
      • Partners
      • Partnership Programs
      • Editorial Guidelines
      • Resources

      Why PRWeb

      • Why PRWeb
      • How It Works
      • Who Uses It
      • Pricing

      Accounts

      • Create a Free Account
      • Log in
      • Contact Us

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact Cision

      Products

      About

      My Services
      • All News Releases
      • Online Member Center
      • ProfNet
      Cision Distribution Helpline
      888-776-0942
      • Legal
      • Site Map
      • RSS
      • Cookie Settings
      Copyright © 2026 Cision US Inc.